deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics
Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer
deCODE genetics and Illumina, Inc. announced the formation of a strategic alliance under which the companies plan to co-develop and commercialize DNA-based diagnostic tests in several major disease areas. The alliance will employ Illumina's platform for high-multiplex single-nucleotide polymorphism (SNP) genotyping to develop tests for gene variants deCODE has previously shown to have impact on the risk of a growing number of common diseases with major public health impact.
Under the terms of the agreement, Illumina will gain access to disease-related biomarkers for joint validation as diagnostic panels to be marketed and sold by Illumina on its forthcoming BeadXpress platform. The companies will share development costs and split the profits from sales of the diagnostics tests.
The alliance will initially focus on the development, validation and commercialization of specific diagnostic tests for variants in genes involved in three disease-related pathways: the gene-encoding leukotriene A4 hydrolase (linked to heart attack); the gene-encoding transcription factor 7-like 2 (TCF7L2) (linked to type 2 diabetes); and the gene encoding BARD1 (linked to breast cancer).
As part of the agreement, Illumina will install its SNP genotyping platform at deCODE, enabling deCODE to expand its contract genotyping business to offer Illumina platform and assay technologies together with deCODE's proprietary analytical services for customers. deCODE will utilize the Illumina platform to carry-out high-density, whole-genome studies utilizing its comprehensive population genetics resources in Iceland including more than 100,000 participants in some 50 common diseases. This effort, which will enhance deCODE's proprietary gene and drug target discovery work and may provide genetic markers for additional diagnostic development.
Other news from the department business & finance
These products might interest you
Genomics & Analytical Services by Azenta
Integrated Genomics & Analytical Services from Azenta Life Sciences
Discovery can be challenging work. Until you find the right genomics partner.
Pharmaceutical Development Services by AR2i
Take Advantage of AR2i's Analytical Knowledge and Unique Expertise
Our Pharmaceutical Laboratory Services According to the European Pharmacopoeia or Client Needs
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
